Clinical Round Up: No glaucoma protection from primary IOL placement in children
August 27th 2015In this month's Clinical Round Up, Sharon Freedman, MD, discusses results of the Infant Aphasia Treatment Study, and how it found there is no glaucoma protection from primary IOL placement in children. Additionally, Barbara Parolini, MD, discusses the new hope for better myopic traction maculopathy outcomes.
Tips for handling the business side of medicine
August 1st 2015n this installment of Sight Lines, J.C. Noreika, MD, MBA, talks with Michael L. Stark, JD, who has represented physicians for more than 50 years as his primary client base. Among the topics they discuss is the watershed moment that enabled physicians to incorporate and take advantage of business-tax deduction provisions.
Therapeutic advances in glaucoma focus on retinal ganglion cell pathology
August 1st 2015Findings from basic science research elucidating the mechanisms of retinal ganglion cell axon degeneration, regeneration, and death have identified new therapeutic targets for glaucoma that are being investigated in preclinical and clinical studies.
Targeting TGF-beta in different ocular diseases
August 1st 2015A potent and selective transforming growth factor (TGF)-β2 LNA-modified antisense oligonucleotide induces biologic responses consistent with the drug’s expected molecular mechanism of action in different preclinical ocular surface disease models.
TCP gains traction as modality for glaucoma cases with good visual potential
August 1st 2015A proprietary glaucoma device has changed current thinking about cyclophotocoagulation by offering another option in the glaucoma treatment algorithm and allowing earlier laser intervention when medical treatment comes up short.